All In Biotech

Drug Trial Radar · NCT05627856

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

4

Actual

Start

Feb 21, 2023

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Nov 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the safety and efficacy of GNC-038 in relapsed or refractory NK/T cell lymphoma, vascular immunomother T cell lymphoma, and other relapsed or refractory NHL, and to determine MTD, MAD, DLT, and RP2D of GNC-038, as well as its pharmacokinetic characteristics and immunogenicity.

Conditions

  • NK/T Cell Lymphoma
  • Vascular Immunomother T Cell Lymphoma
  • Non-Hodgkin Lymphoma

Interventions

  • GNC-038Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Dose Limited Toxicity (DLT)Time frame: Up to 16 days after the first dose
  2. Phase Ib: Maximum Tolerated dose (MTD) or maximum administered dose (MAD)Time frame: Up to 16 days after the first dose
  3. Phase Ib: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
  4. Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 16 days after the first dose
  5. Phase II: Objective response rate (ORR)Time frame: Up to approximately 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.